<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933384</url>
  </required_header>
  <id_info>
    <org_study_id>CF18341A</org_study_id>
    <secondary_id>106DHA0500150</secondary_id>
    <nct_id>NCT03933384</nct_id>
  </id_info>
  <brief_title>Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B</brief_title>
  <official_title>Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taichung Veterans General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir
      (ETV) in the chronic hepatitis B patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With high antiviral potency and low drug resistance rate, both ETV and tenofovir disoproxil
      fumarate (TDF) have been recommended as the first-line antiviral therapy for chronic
      hepatitis B (CHB). However, risk of renal dysfunction remains an issue in TDF long-term
      therapy. Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir and is formulated to
      deliver the active metabolite to target cells more efficiently than TDF at lower doses,
      thereby reducing systemic exposure to tenofovir. Importantly, TAF had improved renal safety
      as compared to TDF. TAF has been approved for treating CHB since 2017; however, it is still
      unknown whether the efficacy and renal safety of TAF is compatible to those of ETV. The
      investigators aim to conduct an open label, randomized controlled trial comparing TAF with
      ETV for assessing their efficacy and renal safety in CHB patients. The eligible CHB patients
      are randomly assigned (1:1) to receive TAF or ETV. After allocation to TAF group or ETV
      group, study subjects will receive therapy for 3 years (144 weeks).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The eligible chronic hepatitis B patients are randomly assigned (1:1) to receive once-daily oral doses of tenofovir alafenamide 25 mg or entecavir 0.5mg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV viral suppression</measure>
    <time_frame>After 48-week therapy of Tenofovir alafenamide or entecavir</time_frame>
    <description>proportion of patients with hepatitis B virus(HBV) ‐DNA suppression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal safety: Change of estimated glomerular filtration rate</measure>
    <time_frame>After 48-week therapy of Tenofovir alafenamide or entecavir</time_frame>
    <description>Change of estimated glomerular filtration rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization alanine aminotransferase (ALT)</measure>
    <time_frame>After 48-week therapy of Tenofovir alafenamide or entecavir</time_frame>
    <description>proportion of patients with ALT normalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss</measure>
    <time_frame>After 48-week therapy of Tenofovir alafenamide or entecavir</time_frame>
    <description>proportion of patients with HBsAg loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss</measure>
    <time_frame>After 48-week therapy of Tenofovir alafenamide or entecavir</time_frame>
    <description>proportion of patients with HBeAg loss</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Viral Hepatitis</condition>
  <arm_group>
    <arm_group_label>Tenofovir alafenamide group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subjects will receive tenofovir alafenamide 25 mg/tab once daily for 3 years (144 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subjects will receive entecavir 0.5 mg/tab once daily for 3 years (144 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir alafenamide</intervention_name>
    <description>Tenofovir alafenamide 25mg/tab once daily</description>
    <arm_group_label>Tenofovir alafenamide group</arm_group_label>
    <other_name>Vemlidy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Entecavir 0.5mg/tab once daily</description>
    <arm_group_label>Entecavir group</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients more than 20 years old

          2. Chronic hepatitis B patients

          3. Patients who were indicated for hepatitis B virus antiviral therapy

        Exclusion Criteria:

          1. Decompensated liver disease (Child-Pugh B &amp;C)

          2. End stage renal disease (eGRF &lt; 15 ml/min/1.73m2)

          3. Prior use of nucleot(s)ide analogues for chronic hepatitis B

          4. Prior use of interferon for chronic hepatitis B within six months

          5. Known history of human immunodeficiency virus or hepatitis C virus co-infection

          6. Concurrent other uncontrolled malignancy

          7. Women in pregnancy or lactation

          8. Cannot conform to the study protocol of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teng-Yu Lee, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teng-Yu Lee, MD, PhD</last_name>
    <phone>886-4-23592525</phone>
    <phone_ext>3301</phone_ext>
    <email>tylee@vghtc.gov.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hsin-Ju Tsai, MD</last_name>
    <phone>886-4-23592525</phone>
    <phone_ext>3301</phone_ext>
    <email>a9194024@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teng-Yu Lee, MD, PhD</last_name>
      <phone>886-4-23592525</phone>
      <phone_ext>3301</phone_ext>
      <email>tylee@vghtc.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006 Oct;45(4):529-38. Epub 2006 Jun 23.</citation>
    <PMID>16879891</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen DS, Sung JL. Hepatitis B virus infection on Taiwan. N Engl J Med. 1977 Sep 22;297(12):668-9.</citation>
    <PMID>757978</PMID>
  </results_reference>
  <results_reference>
    <citation>Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012 Oct;57(4):730-5. doi: 10.1016/j.jhep.2012.05.021. Epub 2012 Jun 2.</citation>
    <PMID>22668640</PMID>
  </results_reference>
  <results_reference>
    <citation>Chiang CJ, Yang YW, Chen JD, You SL, Yang HI, Lee MH, Lai MS, Chen CJ. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology. 2015 Apr;61(4):1154-62. doi: 10.1002/hep.27630. Epub 2015 Feb 10.</citation>
    <PMID>25476749</PMID>
  </results_reference>
  <results_reference>
    <citation>Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800.</citation>
    <PMID>29405329</PMID>
  </results_reference>
  <results_reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.</citation>
    <PMID>28427875</PMID>
  </results_reference>
  <results_reference>
    <citation>Kang L, Pan J, Wu J, Hu J, Sun Q, Tang J. Anti-HBV Drugs: Progress, Unmet Needs, and New Hope. Viruses. 2015 Sep 15;7(9):4960-77. doi: 10.3390/v7092854. Review.</citation>
    <PMID>26389937</PMID>
  </results_reference>
  <results_reference>
    <citation>Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006 Mar 9;354(10):1011-20. Erratum in: N Engl J Med. 2006 Apr 27;354(17):1863.</citation>
    <PMID>16525138</PMID>
  </results_reference>
  <results_reference>
    <citation>Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.</citation>
    <PMID>19052126</PMID>
  </results_reference>
  <results_reference>
    <citation>van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, Wiedenmann B, Berg T. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004 Dec;40(6):1421-5.</citation>
    <PMID>15565615</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsai HJ, Chuang YW, Lee SW, Wu CY, Yeh HZ, Lee TY. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients. Aliment Pharmacol Ther. 2018 Jun;47(12):1673-1681. doi: 10.1111/apt.14682. Epub 2018 Apr 25.</citation>
    <PMID>29696665</PMID>
  </results_reference>
  <results_reference>
    <citation>Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013 Jun 4;158(11):825-30. doi: 10.7326/0003-4819-158-11-201306040-00007.</citation>
    <PMID>23732715</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K; GS-US-320-0110 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):185-195. doi: 10.1016/S2468-1253(16)30024-3. Epub 2016 Sep 22. Erratum in: Lancet Gastroenterol Hepatol. 2016 Nov;1(3):e2.</citation>
    <PMID>28404091</PMID>
  </results_reference>
  <results_reference>
    <citation>Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22. Erratum in: Lancet Gastroenterol Hepatol. 2016 Nov;1(3):e2.</citation>
    <PMID>28404092</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 28, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taichung Veterans General Hospital</investigator_affiliation>
    <investigator_full_name>Teng-Yu Lee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Viral Hepatitis</keyword>
  <keyword>Tenofovir alafenamide</keyword>
  <keyword>Entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

